Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|May 23, 2011
ICON Central Laboratories Launches New Cytometry Services Offering
Advertisement
ICON
announced the launch of a new Cytometry Services offering from its Central Laboratories business unit. ICON Cytometry Services now offers clients two types of services to better support the testing requirements and development phase of a client’s compound.
ICON Cytometry Services’ full service solution allows clients to collaborate with ICON at the early stages of development to create compound-specific assays. Clients work with ICON Central Laboratories’ R&D team to develop a unique Flow Cytometry methodology, customised SOPs and agree on other special requirements including reporting. These customised Flow Cytometry panels can then be used throughout the compound development lifecycle. ICON Cytometry Services’ other service offering enables clients to choose from a wide range of fully validated assays and is often suited to the large scale, high-volume requirements of later phase global trials.
Commenting on the announcement, Tom O’Leary, President, ICON Central Laboratories, said, “Flow Cytometry has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialised testing. Our new Cytometry Services offering provides clients with a better range of options, all of which are supported by a team of highly experienced scientists, robust instrumentation and rigorous quality control systems.”
ICON Central Laboratories offers global Flow Cytometry services from its laboratories in New York, Dublin, Bangalore and Singapore.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
5